Category Archives: leadership

Obamacare's "Unacceptable" Rx Copays

by Tom Norton We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth […]
Also posted in Biotech, Guest Blog, healthcare, Legal, Market Access, Strategy | Tagged , , , , , , , | 2 Comments

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Also posted in Biotech, FDA, healthcare, Manufacturing, Market Access, pricing, R&D, Regulatory, Technology | Tagged , , , , , , | 1 Comment

Eight Ingredients for a Successful Oncology Drug Development Recipe

by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
Also posted in Agency Insight, Biotech, Europe, FDA, Gene therapy, Guest Blog, Market Access, Orphan Drugs, pricing, R&D, Regulatory, Sales | Tagged , , | Leave a comment

Strategic Development Partnerships: Preparing for Inevitable Challenges

by Sydney Rubin It’s hardly news that biopharmaceutical companies today face increasing pressure to innovate, produce, improve efficiency and quality, and reduce costs – all while keeping up with an evolving regulatory environment and getting patients better treatments and outcomes.
Also posted in Advertising, Agency Insight, R&D, Strategy | Leave a comment

Antibiotics Discovery: Time for a ‘Manhattan Project’

by Susan Crowley The innovative pharmaceutical industry is under attack from critics around the world for failing to develop new antibiotics to treat emerging infections. The charge has been furthered by statements from World Health Organization (WHO) director Margaret Chan. In 2012, she warned that bacteria were starting to become so resistant to common antibiotics […]
Also posted in Corporate Responsibility, Global, Guest Blog, healthcare, IP, Manufacturing, Market Access, R&D, Strategy | Tagged , , , , , , , | 4 Comments
  • Categories

  • Meta